HemaCore is a biotech company, develops medical devices and methods for hematology. HemaCore was founded in April, 2010 by a group of scientist who invented and patented the Thrombodynamics – a new global assay for monitoring and prognosis of blood coagulation disorders: bleeding and thrombosis, precursors of heart attacks and strokes. In 2010 HemaCore received the first round of investments from RUSNANO and Sberbank Capital intended for developing the analyser, consumables and organization of clinical trials in Russia. HemaCore has completed final design of product for the serial production of the Thrombodynamics analyzer and disposables. In Europe and USA: Research Use Only.

More

Thrombodynamics: a new global assay for monitoring and prognosis of blood coagulation disorders: bleeding and thrombosis, precursors of heart attacks and strokes. This in vitro assay, which mimics clotting processes occurring in vivo in a wound, is based on a reaction-diffusion experimental model of blood coagulation. Thrombodynamics analyser enables to evaluate different phases of blood coagulation and diagnose the increased (leading to thromboses, heart attacks and strokes), decreased (hemorrhages and hemophilia) and combined (DIC-syndrome, sepsis) forms of the blood coagulation disorders. In Europe and USA: Research Use Only.